nodes	percent_of_prediction	percent_of_DWPC	metapath
Verteporfin—Infusion related reaction—Capecitabine—esophageal cancer	0.109	0.109	CcSEcCtD
Verteporfin—Extravasation—Carboplatin—esophageal cancer	0.0544	0.0544	CcSEcCtD
Verteporfin—Varicose vein—Capecitabine—esophageal cancer	0.0275	0.0275	CcSEcCtD
Verteporfin—Sunburn—Methotrexate—esophageal cancer	0.0253	0.0253	CcSEcCtD
Verteporfin—Visual acuity reduced—Capecitabine—esophageal cancer	0.0172	0.0172	CcSEcCtD
Verteporfin—Raised liver function tests—Methotrexate—esophageal cancer	0.0165	0.0165	CcSEcCtD
Verteporfin—Extravasation—Cisplatin—esophageal cancer	0.0159	0.0159	CcSEcCtD
Verteporfin—Hearing impaired—Cisplatin—esophageal cancer	0.0146	0.0146	CcSEcCtD
Verteporfin—Pain—Carboplatin—esophageal cancer	0.0145	0.0145	CcSEcCtD
Verteporfin—Blister—Capecitabine—esophageal cancer	0.0142	0.0142	CcSEcCtD
Verteporfin—Body temperature increased—Carboplatin—esophageal cancer	0.0134	0.0134	CcSEcCtD
Verteporfin—Hyperaesthesia—Capecitabine—esophageal cancer	0.0131	0.0131	CcSEcCtD
Verteporfin—Injection site pain—Capecitabine—esophageal cancer	0.0126	0.0126	CcSEcCtD
Verteporfin—Hearing impaired—Capecitabine—esophageal cancer	0.0108	0.0108	CcSEcCtD
Verteporfin—Cataract—Capecitabine—esophageal cancer	0.0108	0.0108	CcSEcCtD
Verteporfin—Inflammation—Capecitabine—esophageal cancer	0.0106	0.0106	CcSEcCtD
Verteporfin—Injection site reaction—Capecitabine—esophageal cancer	0.0102	0.0102	CcSEcCtD
Verteporfin—Dry eye—Capecitabine—esophageal cancer	0.00947	0.00947	CcSEcCtD
Verteporfin—Blood creatinine increased—Cisplatin—esophageal cancer	0.00946	0.00946	CcSEcCtD
Verteporfin—Extravasation—Methotrexate—esophageal cancer	0.00875	0.00875	CcSEcCtD
Verteporfin—Sleep disorder—Capecitabine—esophageal cancer	0.0086	0.0086	CcSEcCtD
Verteporfin—Photosensitivity—Capecitabine—esophageal cancer	0.00848	0.00848	CcSEcCtD
Verteporfin—Inflammation—Methotrexate—esophageal cancer	0.00787	0.00787	CcSEcCtD
Verteporfin—Atrial fibrillation—Capecitabine—esophageal cancer	0.00786	0.00786	CcSEcCtD
Verteporfin—Dermatitis bullous—Capecitabine—esophageal cancer	0.00779	0.00779	CcSEcCtD
Verteporfin—Acute coronary syndrome—Cisplatin—esophageal cancer	0.00767	0.00767	CcSEcCtD
Verteporfin—Myocardial infarction—Cisplatin—esophageal cancer	0.00763	0.00763	CcSEcCtD
Verteporfin—Conjunctivitis—Cisplatin—esophageal cancer	0.00757	0.00757	CcSEcCtD
Verteporfin—Osteoarthritis—Capecitabine—esophageal cancer	0.00745	0.00745	CcSEcCtD
Verteporfin—Diplopia—Capecitabine—esophageal cancer	0.00745	0.00745	CcSEcCtD
Verteporfin—Blood creatinine increased—Capecitabine—esophageal cancer	0.00697	0.00697	CcSEcCtD
Verteporfin—Liver function test abnormal—Capecitabine—esophageal cancer	0.00687	0.00687	CcSEcCtD
Verteporfin—Visual impairment—Cisplatin—esophageal cancer	0.00673	0.00673	CcSEcCtD
Verteporfin—Muscular weakness—Capecitabine—esophageal cancer	0.00657	0.00657	CcSEcCtD
Verteporfin—Eye disorder—Cisplatin—esophageal cancer	0.00653	0.00653	CcSEcCtD
Verteporfin—Cardiac disorder—Cisplatin—esophageal cancer	0.00648	0.00648	CcSEcCtD
Verteporfin—Flushing—Cisplatin—esophageal cancer	0.00648	0.00648	CcSEcCtD
Verteporfin—Influenza—Capecitabine—esophageal cancer	0.00643	0.00643	CcSEcCtD
Verteporfin—Photosensitivity—Methotrexate—esophageal cancer	0.00631	0.00631	CcSEcCtD
Verteporfin—Immune system disorder—Cisplatin—esophageal cancer	0.00631	0.00631	CcSEcCtD
Verteporfin—Malnutrition—Cisplatin—esophageal cancer	0.00608	0.00608	CcSEcCtD
Verteporfin—Photosensitivity reaction—Capecitabine—esophageal cancer	0.00587	0.00587	CcSEcCtD
Verteporfin—Visual disturbance—Methotrexate—esophageal cancer	0.00585	0.00585	CcSEcCtD
Verteporfin—Pneumonia—Capecitabine—esophageal cancer	0.00577	0.00577	CcSEcCtD
Verteporfin—Vision blurred—Cisplatin—esophageal cancer	0.00573	0.00573	CcSEcCtD
Verteporfin—Acute coronary syndrome—Capecitabine—esophageal cancer	0.00566	0.00566	CcSEcCtD
Verteporfin—Ill-defined disorder—Cisplatin—esophageal cancer	0.00564	0.00564	CcSEcCtD
Verteporfin—Myocardial infarction—Capecitabine—esophageal cancer	0.00562	0.00562	CcSEcCtD
Verteporfin—Anaemia—Cisplatin—esophageal cancer	0.00562	0.00562	CcSEcCtD
Verteporfin—Conjunctivitis—Capecitabine—esophageal cancer	0.00558	0.00558	CcSEcCtD
Verteporfin—Osteoarthritis—Methotrexate—esophageal cancer	0.00554	0.00554	CcSEcCtD
Verteporfin—Malaise—Cisplatin—esophageal cancer	0.00549	0.00549	CcSEcCtD
Verteporfin—Haemoglobin—Capecitabine—esophageal cancer	0.00518	0.00518	CcSEcCtD
Verteporfin—Haemorrhage—Capecitabine—esophageal cancer	0.00515	0.00515	CcSEcCtD
Verteporfin—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.00514	0.00514	CcSEcCtD
Verteporfin—Hypoaesthesia—Capecitabine—esophageal cancer	0.00512	0.00512	CcSEcCtD
Verteporfin—Liver function test abnormal—Methotrexate—esophageal cancer	0.00512	0.00512	CcSEcCtD
Verteporfin—Discomfort—Cisplatin—esophageal cancer	0.00512	0.00512	CcSEcCtD
Verteporfin—Pharyngitis—Capecitabine—esophageal cancer	0.00511	0.00511	CcSEcCtD
Verteporfin—Oedema—Cisplatin—esophageal cancer	0.00496	0.00496	CcSEcCtD
Verteporfin—Visual impairment—Capecitabine—esophageal cancer	0.00496	0.00496	CcSEcCtD
Verteporfin—Nervous system disorder—Cisplatin—esophageal cancer	0.00487	0.00487	CcSEcCtD
Verteporfin—Skin disorder—Cisplatin—esophageal cancer	0.00482	0.00482	CcSEcCtD
Verteporfin—Eye disorder—Capecitabine—esophageal cancer	0.00481	0.00481	CcSEcCtD
Verteporfin—Hyperhidrosis—Cisplatin—esophageal cancer	0.0048	0.0048	CcSEcCtD
Verteporfin—Cardiac disorder—Capecitabine—esophageal cancer	0.00478	0.00478	CcSEcCtD
Verteporfin—Flushing—Capecitabine—esophageal cancer	0.00478	0.00478	CcSEcCtD
Verteporfin—Angiopathy—Capecitabine—esophageal cancer	0.00467	0.00467	CcSEcCtD
Verteporfin—Immune system disorder—Capecitabine—esophageal cancer	0.00465	0.00465	CcSEcCtD
Verteporfin—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.00452	0.00452	CcSEcCtD
Verteporfin—Malnutrition—Capecitabine—esophageal cancer	0.00448	0.00448	CcSEcCtD
Verteporfin—Dyspnoea—Cisplatin—esophageal cancer	0.00443	0.00443	CcSEcCtD
Verteporfin—Photosensitivity reaction—Methotrexate—esophageal cancer	0.00437	0.00437	CcSEcCtD
Verteporfin—Back pain—Capecitabine—esophageal cancer	0.00434	0.00434	CcSEcCtD
Verteporfin—Pneumonia—Methotrexate—esophageal cancer	0.0043	0.0043	CcSEcCtD
Verteporfin—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.00429	0.00429	CcSEcCtD
Verteporfin—Pain—Cisplatin—esophageal cancer	0.00425	0.00425	CcSEcCtD
Verteporfin—Vision blurred—Capecitabine—esophageal cancer	0.00423	0.00423	CcSEcCtD
Verteporfin—Ill-defined disorder—Capecitabine—esophageal cancer	0.00416	0.00416	CcSEcCtD
Verteporfin—Conjunctivitis—Methotrexate—esophageal cancer	0.00415	0.00415	CcSEcCtD
Verteporfin—Anaemia—Capecitabine—esophageal cancer	0.00414	0.00414	CcSEcCtD
Verteporfin—Sweating—Methotrexate—esophageal cancer	0.00409	0.00409	CcSEcCtD
Verteporfin—Feeling abnormal—Cisplatin—esophageal cancer	0.00409	0.00409	CcSEcCtD
Verteporfin—Malaise—Capecitabine—esophageal cancer	0.00404	0.00404	CcSEcCtD
Verteporfin—Vertigo—Capecitabine—esophageal cancer	0.00403	0.00403	CcSEcCtD
Verteporfin—Syncope—Capecitabine—esophageal cancer	0.00402	0.00402	CcSEcCtD
Verteporfin—Loss of consciousness—Capecitabine—esophageal cancer	0.00394	0.00394	CcSEcCtD
Verteporfin—Body temperature increased—Cisplatin—esophageal cancer	0.00392	0.00392	CcSEcCtD
Verteporfin—Cough—Capecitabine—esophageal cancer	0.00391	0.00391	CcSEcCtD
Verteporfin—Hypertension—Capecitabine—esophageal cancer	0.00387	0.00387	CcSEcCtD
Verteporfin—Haemoglobin—Methotrexate—esophageal cancer	0.00385	0.00385	CcSEcCtD
Verteporfin—Haemorrhage—Methotrexate—esophageal cancer	0.00383	0.00383	CcSEcCtD
Verteporfin—Arthralgia—Capecitabine—esophageal cancer	0.00382	0.00382	CcSEcCtD
Verteporfin—Chest pain—Capecitabine—esophageal cancer	0.00382	0.00382	CcSEcCtD
Verteporfin—Pharyngitis—Methotrexate—esophageal cancer	0.00381	0.00381	CcSEcCtD
Verteporfin—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.00379	0.00379	CcSEcCtD
Verteporfin—Discomfort—Capecitabine—esophageal cancer	0.00377	0.00377	CcSEcCtD
Verteporfin—Visual impairment—Methotrexate—esophageal cancer	0.0037	0.0037	CcSEcCtD
Verteporfin—Oedema—Capecitabine—esophageal cancer	0.00366	0.00366	CcSEcCtD
Verteporfin—Hypersensitivity—Cisplatin—esophageal cancer	0.00366	0.00366	CcSEcCtD
Verteporfin—Shock—Capecitabine—esophageal cancer	0.0036	0.0036	CcSEcCtD
Verteporfin—Nervous system disorder—Capecitabine—esophageal cancer	0.00359	0.00359	CcSEcCtD
Verteporfin—Eye disorder—Methotrexate—esophageal cancer	0.00358	0.00358	CcSEcCtD
Verteporfin—Asthenia—Cisplatin—esophageal cancer	0.00356	0.00356	CcSEcCtD
Verteporfin—Cardiac disorder—Methotrexate—esophageal cancer	0.00356	0.00356	CcSEcCtD
Verteporfin—Skin disorder—Capecitabine—esophageal cancer	0.00355	0.00355	CcSEcCtD
Verteporfin—Hyperhidrosis—Capecitabine—esophageal cancer	0.00354	0.00354	CcSEcCtD
Verteporfin—Angiopathy—Methotrexate—esophageal cancer	0.00348	0.00348	CcSEcCtD
Verteporfin—Immune system disorder—Methotrexate—esophageal cancer	0.00346	0.00346	CcSEcCtD
Verteporfin—Malnutrition—Methotrexate—esophageal cancer	0.00334	0.00334	CcSEcCtD
Verteporfin—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.00333	0.00333	CcSEcCtD
Verteporfin—Dyspnoea—Capecitabine—esophageal cancer	0.00326	0.00326	CcSEcCtD
Verteporfin—Back pain—Methotrexate—esophageal cancer	0.00323	0.00323	CcSEcCtD
Verteporfin—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.00316	0.00316	CcSEcCtD
Verteporfin—Vision blurred—Methotrexate—esophageal cancer	0.00315	0.00315	CcSEcCtD
Verteporfin—Rash—Cisplatin—esophageal cancer	0.00313	0.00313	CcSEcCtD
Verteporfin—Constipation—Capecitabine—esophageal cancer	0.00313	0.00313	CcSEcCtD
Verteporfin—Pain—Capecitabine—esophageal cancer	0.00313	0.00313	CcSEcCtD
Verteporfin—Dermatitis—Cisplatin—esophageal cancer	0.00313	0.00313	CcSEcCtD
Verteporfin—Ill-defined disorder—Methotrexate—esophageal cancer	0.0031	0.0031	CcSEcCtD
Verteporfin—Anaemia—Methotrexate—esophageal cancer	0.00308	0.00308	CcSEcCtD
Verteporfin—Feeling abnormal—Capecitabine—esophageal cancer	0.00302	0.00302	CcSEcCtD
Verteporfin—Malaise—Methotrexate—esophageal cancer	0.00301	0.00301	CcSEcCtD
Verteporfin—Vertigo—Methotrexate—esophageal cancer	0.003	0.003	CcSEcCtD
Verteporfin—Nausea—Cisplatin—esophageal cancer	0.00295	0.00295	CcSEcCtD
Verteporfin—Cough—Methotrexate—esophageal cancer	0.00291	0.00291	CcSEcCtD
Verteporfin—Urticaria—Capecitabine—esophageal cancer	0.00291	0.00291	CcSEcCtD
Verteporfin—Body temperature increased—Capecitabine—esophageal cancer	0.00289	0.00289	CcSEcCtD
Verteporfin—Chest pain—Methotrexate—esophageal cancer	0.00284	0.00284	CcSEcCtD
Verteporfin—Arthralgia—Methotrexate—esophageal cancer	0.00284	0.00284	CcSEcCtD
Verteporfin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.00282	0.00282	CcSEcCtD
Verteporfin—Discomfort—Methotrexate—esophageal cancer	0.00281	0.00281	CcSEcCtD
Verteporfin—Hypersensitivity—Capecitabine—esophageal cancer	0.0027	0.0027	CcSEcCtD
Verteporfin—Nervous system disorder—Methotrexate—esophageal cancer	0.00267	0.00267	CcSEcCtD
Verteporfin—Skin disorder—Methotrexate—esophageal cancer	0.00265	0.00265	CcSEcCtD
Verteporfin—Hyperhidrosis—Methotrexate—esophageal cancer	0.00263	0.00263	CcSEcCtD
Verteporfin—Asthenia—Capecitabine—esophageal cancer	0.00263	0.00263	CcSEcCtD
Verteporfin—Pruritus—Capecitabine—esophageal cancer	0.00259	0.00259	CcSEcCtD
Verteporfin—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.00248	0.00248	CcSEcCtD
Verteporfin—Dyspnoea—Methotrexate—esophageal cancer	0.00243	0.00243	CcSEcCtD
Verteporfin—Dizziness—Capecitabine—esophageal cancer	0.00242	0.00242	CcSEcCtD
Verteporfin—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.00235	0.00235	CcSEcCtD
Verteporfin—Pain—Methotrexate—esophageal cancer	0.00233	0.00233	CcSEcCtD
Verteporfin—Rash—Capecitabine—esophageal cancer	0.00231	0.00231	CcSEcCtD
Verteporfin—Dermatitis—Capecitabine—esophageal cancer	0.00231	0.00231	CcSEcCtD
Verteporfin—Headache—Capecitabine—esophageal cancer	0.00229	0.00229	CcSEcCtD
Verteporfin—Feeling abnormal—Methotrexate—esophageal cancer	0.00224	0.00224	CcSEcCtD
Verteporfin—Nausea—Capecitabine—esophageal cancer	0.00217	0.00217	CcSEcCtD
Verteporfin—Urticaria—Methotrexate—esophageal cancer	0.00216	0.00216	CcSEcCtD
Verteporfin—Body temperature increased—Methotrexate—esophageal cancer	0.00215	0.00215	CcSEcCtD
Verteporfin—Hypersensitivity—Methotrexate—esophageal cancer	0.00201	0.00201	CcSEcCtD
Verteporfin—Asthenia—Methotrexate—esophageal cancer	0.00195	0.00195	CcSEcCtD
Verteporfin—Pruritus—Methotrexate—esophageal cancer	0.00193	0.00193	CcSEcCtD
Verteporfin—Dizziness—Methotrexate—esophageal cancer	0.0018	0.0018	CcSEcCtD
Verteporfin—Rash—Methotrexate—esophageal cancer	0.00172	0.00172	CcSEcCtD
Verteporfin—Dermatitis—Methotrexate—esophageal cancer	0.00172	0.00172	CcSEcCtD
Verteporfin—Headache—Methotrexate—esophageal cancer	0.00171	0.00171	CcSEcCtD
Verteporfin—Nausea—Methotrexate—esophageal cancer	0.00162	0.00162	CcSEcCtD
